JP2004525150A5 - - Google Patents

Download PDF

Info

Publication number
JP2004525150A5
JP2004525150A5 JP2002576967A JP2002576967A JP2004525150A5 JP 2004525150 A5 JP2004525150 A5 JP 2004525150A5 JP 2002576967 A JP2002576967 A JP 2002576967A JP 2002576967 A JP2002576967 A JP 2002576967A JP 2004525150 A5 JP2004525150 A5 JP 2004525150A5
Authority
JP
Japan
Prior art keywords
alkyl
group
aryl
heterocyclyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002576967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525150A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/008621 external-priority patent/WO2002078701A1/en
Publication of JP2004525150A publication Critical patent/JP2004525150A/ja
Publication of JP2004525150A5 publication Critical patent/JP2004525150A5/ja
Withdrawn legal-status Critical Current

Links

JP2002576967A 2001-03-30 2002-03-20 治療用化合物としてのピラゾロピリジン類の使用 Withdrawn JP2004525150A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28004701P 2001-03-30 2001-03-30
US30718901P 2001-07-23 2001-07-23
PCT/US2002/008621 WO2002078701A1 (en) 2001-03-30 2002-03-20 Use of pyrazolopyridines as therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2004525150A JP2004525150A (ja) 2004-08-19
JP2004525150A5 true JP2004525150A5 (enExample) 2005-12-22

Family

ID=26960034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002576967A Withdrawn JP2004525150A (ja) 2001-03-30 2002-03-20 治療用化合物としてのピラゾロピリジン類の使用

Country Status (4)

Country Link
US (1) US20050107400A1 (enExample)
EP (1) EP1372642A1 (enExample)
JP (1) JP2004525150A (enExample)
WO (1) WO2002078701A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1377573B1 (en) * 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
JP4219171B2 (ja) * 2001-04-10 2009-02-04 スミスクライン ビーチャム コーポレーション 抗ウイルス性ピラゾロピリジン化合物
ES2286272T3 (es) * 2001-09-07 2007-12-01 Smithkline Beecham Corporation Pirizolo-piridinas para el tratamiento de infecciones por herpes.
ATE302203T1 (de) * 2002-03-07 2005-09-15 Smithkline Beecham Corp Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004033454A1 (en) * 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
US7087755B1 (en) * 2004-11-12 2006-08-08 Frontier Scientific, Inc. Substituted pyridines
US7485725B1 (en) 2004-11-12 2009-02-03 Frontier Scientific, Inc. Substituted pyridines
WO2006055245A2 (en) * 2004-11-17 2006-05-26 Smithkline Beecham Corporation Process for preparing pyrazolopyridine compounds
ATE478067T1 (de) 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2924023A1 (en) 2008-06-30 2015-09-30 Janssen Pharmaceutica NV piperidine und piperazine derivativs
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
PE20120325A1 (es) * 2009-05-19 2012-04-12 Dow Agrosciences Llc Aminopirimidinas sustituidas con arilo como agentes fungicidas
US20110039873A1 (en) * 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US8324212B2 (en) 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
AR081810A1 (es) * 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
EP2402336A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402335A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
MX389479B (es) 2011-09-02 2025-03-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k)
IN2014CN02475A (enExample) * 2011-10-06 2015-06-19 Bayer Ip Gmbh
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
JO3516B1 (ar) 2013-03-06 2020-07-05 Janssen Pharmaceutica Nv مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
SG10201912302VA (en) 2015-02-27 2020-02-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
AU2017275599B2 (en) 2016-06-03 2021-09-02 Basf Se Benzoxaborole compounds
BR112019008661A2 (pt) 2016-11-28 2019-07-09 Basf Se composto de diaminotriazina, composição agroquímica, método para o controle da vegetação indesejada e utilização do composto
BR112020010176B1 (pt) 2017-11-22 2023-12-19 Basf Se Uso de compostos, compostos de fórmula (i), composição agroquímica e método de controle de vegetação indesejada
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
WO2020058009A1 (en) 2018-09-18 2020-03-26 Basf Se Diaminotriazine compounds
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
CA3205683A1 (en) 2021-01-27 2022-08-04 Danny GEERDINK Diaminotriazine compounds
WO2022161802A1 (en) 2021-01-27 2022-08-04 Basf Se Diaminotriazine compounds
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151962A3 (en) * 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
GB8404584D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
GB8404586D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
AU622330B2 (en) * 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5300478A (en) * 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
ATE301457T1 (de) * 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
FR2757166B1 (fr) * 1996-12-12 1999-01-29 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
EP1377573B1 (en) * 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
US7153855B2 (en) * 2001-03-08 2006-12-26 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds

Similar Documents

Publication Publication Date Title
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
JP2020037585A5 (enExample)
RU2457209C2 (ru) Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
EP4458834A3 (en) Heterocyclic glp-1 agonists
CY1117459T1 (el) Παραγωγα που εχουν δραση αγωνιστη του βητα-2 αδρενεργικου υποδοχεα και ανταγωνιστη του μουσκαρινικου υποδοχεα
JP2018507890A5 (enExample)
JP2006517939A5 (enExample)
JP2009542716A5 (enExample)
JP2005523922A5 (enExample)
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
JP2020500182A5 (enExample)
JP2004520324A5 (enExample)
JP2020507589A5 (enExample)
JP2009519243A5 (enExample)
JP2004175807A5 (enExample)
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
JP2005538975A5 (enExample)
JP2005514366A5 (enExample)
JP2019535723A5 (enExample)
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
JP2015508092A5 (enExample)
JP2010500962A5 (enExample)
JP2019510027A5 (enExample)
JP2007510662A5 (enExample)
JP2007505931A5 (enExample)